linjc16/ctgov huggingface dataset:
Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate CGM glycemic control using the Dexcom G4 system as well as system performance during high levels of activity and home use by adult athletes with insulin-requiring diabetes mellitus, over an extended period of time.

Official Title
-----------------
Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: Dexcom G4 CGM System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Diagnosis of diabetes mellitus Exclusion Criteria: Extensive skin changes/diseases Known allergy to medical adhesives Pregnancy Dialysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Athletes with diabetes mellitus<br>Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time | Device: Dexcom G4 CGM System<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic Control during Exercise | The proportion of time spent in euglycemia zone as well as hypoglycemia zone will be determined from the system glucose readings, particularly during subject's high levels of activity. Longitudinal data analysis methods will be used to assess the within-subject and between-subject effects of the glycemic control for the study population. | multiple months, up to 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| System Utility and Usability | The objectives of the study are to evaluate the Dexcom G4 system utility and usability during high levels of activity and home use. The assessments may be evaluated by, but are not limited to, the following: Number and duration of sensors used by subject Percentage of CGM system communication during wear Percentage of CGM system glucose reading during wear Incidence of System prompts and error messages recorded in the receiver | multiple months, up to 6 |
The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.

Study Overview
=================
Brief Summary
-----------------
Recently, a lot of evidence for a relation between measures of cognitive performance and personality characteristics has been collected. The use of computer based latency measures is often used to study mental processes in cognitive, as well as, in personality research On the basis of these relationships we can ask a question that relates to the practical usefulness (validity) of processing speed, accuracy of performance and personality measures in predicting impulsive behavior.

Official Title
-----------------
The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women at age - 20-50 years Exclusion Criteria: History of psychiatric disorders, previous hospitalizations and psychopharmacological treatments History of alcohol and substance abuse

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PERSONALITY, COGNITIVE PERFORMANCE, the practical usefulness (validity) of processing speed, accuracy of performance and personality measures in predicting impulsive behavior
Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility

Study Overview
=================
Brief Summary
-----------------
To demonstrate the absence of irritation potential (primary dermical irritability and cumulated dermical irritability) and allergy (sensibilization) of the product Dermacyd PHDETINLYN Sweet Flower.

Official Title
-----------------
Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower

Conditions
-----------------
Hygiene

Intervention / Treatment
-----------------
* Drug: Dermacyd PH_DETINLYN (Lactic Acid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Phototype Skin I,II, III e IV Integral skin test in the region; Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: Lactation or gestation Use of Antiinflammatory and/or immunossupression drugs Personnel history of atopy The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. History of sensitivity or irritation for topic products; Active cutaneous disease; Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Dermacyd PH_DETINLYN (Lactic Acid) | Drug: Dermacyd PH_DETINLYN (Lactic Acid)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale. |  | Throughout the study |
Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI) assessment of disease severity and to investigate the safety of and tolerability of 3% GW842470X cream on diseased skin of adult patients.

Official Title
-----------------
Randomised, Double-blind, Placebo-controlled Study of Topical GW842470X Formulation in Adults With Moderate Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis, Dermatitis, Atopic

Intervention / Treatment
-----------------
* Drug: GW842470X cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Moderate atopic dermatitis patients (IGA=3). The disease involvement must be >5% of body surface area. Female patients of child-bearing potential must use an appropriate method of contraception. Exclusion criteria: Patients with any active skin disease other than atopic dermatitis will not be eligible. Patients who have had systemic treatment for atopic dermatitis or other topical or transdermal treatments (such as nicotine, hormone replacement therapies) within 14 days prior to first application of study medication and/or topical treatment with tar, any corticosteroid, topical immunomodulators or oral treatment with any corticosteroids within 10 days prior to first application and/or oral anti-histamines within 5 days of the first dose.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GW842470X cream|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical efficacy of 3% GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of 3% GW842470X cream |  |  | 
| Clinical efficacy using SCORing Atopic Dermatitis score & Investigators Global Assessment Scale |  |  | 
| Symptoms: pruritus & sleep loss |  |  | 
| Characterize systemic exposure to GW842470X following 21 days treatment. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atopic dermatitis, GW842470X, PDE4 inhibitor
The Turkish Deglutition Handicap Index

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the reliability and validity of the The Turkish Deglutition Handicap Index among adult patients with swallowing disorders.

Detailed Description
-----------------
The purpose of this study is to test the reliability and validity of the The Turkish Deglutition Handicap Index among adult patients with swallowing disorders.The internal consistency, test-retest reliability, and criterion validity of the instrument will be investigated. The internal consistency will be assessed using Cronbach's alpha. Intraclass correlation coefficient (ICC) value with 95 % confidence intervals will be calculated for test-retest reliability. The criterion validity of the scale will be determined by assessing the correlation between The Turkish Deglutition Handicap Index and Turkish Eating Assessment Tool.

Official Title
-----------------
The Turkish Version of the Deglutition Handicap Index

Conditions
-----------------
Swallowing Disorder

Intervention / Treatment
-----------------
* Other: Turkish Deglutition Handicap Index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to participate Having swallowing problems Exclusion Criteria: Being under the age of 20 years, and above the age of 60 years Not willing to participate Having no swallowing problems

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult patients with swallowing disorders<br>Swallowing function will be evaluated with the Turkish Deglutition Handicap Index, and Turkish version of the Eating Assessment Tool. | Other: Turkish Deglutition Handicap Index<br>* Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Turkish Deglutition Handicap Index | Turkish Deglutition Handicap Index is a swallowing function evaluation tool. The test consists of 30 items which will be scored between 0 to 4. 0 means Never, and 4 means Always. The test score ranges from 30 (minimum) to 120 (maximum) points. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Turkish version of the Eating Assessment Tool-10 | The Turkish version of the Eating Assessment Tool-10 is a self-reporting instrument with 10 questions. Total score ranges between 0 to 40. Higher scores indicate worse swallowing function. | 3 months |
Preoperative Hepatic Arterial Infusion Chemotherapy

Study Overview
=================
Brief Summary
-----------------
To assess the feasibility and results of liver resection after preoperative hepatic artery infusion (HAI) chemotherapy with FUDR.

Detailed Description
-----------------
Between 1995 and 2004, 239 patients with isolated colorectal liver metastases received HAI chemotherapy with neoadjuvant intent. Fifty of these patients underwent subsequent curative liver resection (HAI group). Postoperative morbidity, liver function tests, and long term outcomes were evaluated. Adverse events related to HAI chemotherapy were also evaluated.

Official Title
-----------------
Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases

Conditions
-----------------
Colorectal Liver Metastases

Intervention / Treatment
-----------------
* Drug: Floxuridine FUDR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unresectable liver metastases Potentially resectable liver metastases Exclusion Criteria: Extrahepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Floxuridine FUDR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Neuroradiolological Analysis of COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
To describe the radiological presentation of brain abnormalities in COVID-19 + patients

Official Title
-----------------
Imaging Analysis of COVID-19 + Patients With Abnormal Neurological Examination

Conditions
-----------------
Covid-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults COVID-19 + Abnormal neurological examination who underwent a brain MRI Exclusion Criteria: No participation agreement Non COVID-19 patients Patients COVID-19 + without neurological abnormality or without MRI examination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuroradiological analysis of patients brain MRI |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, MRI, Brain
Total Laparoscopic Hystrectomy Versus Total Abdominal Hystrectomy

Study Overview
=================
Brief Summary
-----------------
100 patient will be recruited for hystrectomy for benign cause and TLH will be copared to TAH and effect of learning curve will be assessed by comparing operative time between early and lat patients in TLH group

Official Title
-----------------
Total Laparoscopic Hystrectomy Versus Total Abdominal Hystrectomy: the Effect of Learning Curve a Randomized Controlled Trial

Conditions
-----------------
Effect of Learning Curve on Operative Time in TLH and Comparing it to TAH

Intervention / Treatment
-----------------
* Procedure: Hystrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Age. More than 40 Uterine size less than 14 weeks No contraindications for laparscopic surgery Benign cause for hystrectomy Exclusion Criteria: virgins Malignancy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Total laparscopic hystrectomy<br> | Procedure: Hystrectomy<br>* Total laparscopic hystrectomy versus total abdominal hystrectomy<br>|
| Experimental: Total abdominal hystrectomy<br> | Procedure: Hystrectomy<br>* Total laparscopic hystrectomy versus total abdominal hystrectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operative time | Time in both type of hystrectomy will be compared and learning curve will be assesd among TLH group by comparing early cases to late | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood loss, coplications, postoperative pain | Hb measurment , and visual scale for pain | 2 years |
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin, cisplatin and capecitabine). In addition the study will look at pharmacokinetic (how the the body takes up the drug) and pharmacodynamic parameters (what the drug does in the body).

Official Title
-----------------
A Phase I Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma

Conditions
-----------------
Esophageal Cancer, Gastric Cancer

Intervention / Treatment
-----------------
* Drug: EMD 72000 (matuzumab) + ECX


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced, recurrent or metastatic gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus EGFR positive tumor KPS greater than 60 Normal cardiac function Adequate liver and bone marrow function GFR greater than 60 ml/minute Exclusion Criteria: Previous chemotherapy Uncontrolled angina pectoris, heart failure, clinically significant uncontrolled cardiac arrythmias Clinically significant ECG or cardiac history Radiotherapy or surgery within last 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: EMD 72000 (matuzumab) + ECX|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacodynamic parameters |  |  | 
| Pharmacokinetic parameters |  |  | 
| Response rate |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EMD 72000, matuzumab, Esophageal adenocarcinoma, Gastric adenocarcinoma
Is it Possible to Treat Cyanide Poisoning With HBO?

Study Overview
=================
Brief Summary
-----------------
People who has been in a fire accident have been shown often to be cyanide poisoned as well as poisoned with carbon monoxide(CO). According to recommendations from the Danish Health Agency people who are CO poisoned must be treated with hyperbaric oxygen (HBO). We want to see if HBO treatment can also treat cyanide poisoning. The hypothesis is that as cyanide binds the same place in the mitochondria as CO cyanide will be detached from the mitochondria like CO and diffuse back to the blood.This way it will be easier to treat with hydroxycobalamin.

Conditions
-----------------
Carbon Monoxide Poisoning From Fire Accidents

Intervention / Treatment
-----------------
* Procedure: HBO - hyperbaric oxygen treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Going to receive HBO treatment for carbon monoxide poisoning from fire accidents Exclusion Criteria: Under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: HBO - hyperbaric oxygen treatment|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction

Study Overview
=================
Brief Summary
-----------------
Hormonal imbalances are likely to affect the corneal metabolism and may be also associated with Keratoconus. Among the various endocrinologic dysfunctions assumed so far, thyroid gland dysfunction (TGD) (hypo- or hyperthyroidism; comprised as TGD) is frequently associated with eye diseases such as Graves disease

Detailed Description
-----------------
Aim of the work We aim to examine the prevalence of KC among patients already diagnosed by endocrinologist with TGD. Materials and methods Our Screening for KC will include evaluation of the demographic data and complete ophthalmological examination of the patients using: VA Refraction K reading Slit lamp examination Pentacam Study design Epidemiological study Inclusion citeria All patients diagnosed as thyroid gland dysfunction Control group Exclusion criteria Uncooperative patients

Official Title
-----------------
Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction

Conditions
-----------------
Keratoconus in Thyroid Gland Dysfunction

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients diagnosed as thyroid gland dysfunction Exclusion Criteria: Uncooperative patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of keratoconus in thyroid gland dysfunction | Our Screening for KC will include evaluation of the demographic data and complete ophthalmological examination of the patients using: VA Refraction K reading Slit lamp examination Pentacam | we will recruit patients who meer the inclusion criteria during the study period April-August 2020 |